Q-omics provides the consensus-scored ZNF615 profile across patient tissues and cancer cell-line models. ZNF615 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF615 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, ZNF615 RNA expression shows 20,736 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where ZNF615 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF615 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF615 survival associations across molecular data types. ZNF615 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF615 RNA expression–survival associations across cancer types. High ZNF615 expression shows unfavorable associations in STAD, LGG, CESC, LIHC and MESO, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF615 RNA expression.
This table summarizes ZNF615 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF615. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF615 shows lower tumor expression in KICH, THCA and COAD and higher tumor expression in LIHC, CHOL and PRAD. The KICH box plot shows higher ZNF615 RNA expression in normal versus tumor tissue (log2 FC = −1.261, t-test p < 0.001).
This table shows molecular features associated with ZNF615 in patient tissues and cancer cell lines. In patient samples, ZNF615 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF615 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SOFT_TISSUE.
